Supplementary Figure 3 from Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multiomics Platform
Authors:Frank A. Sinicrope, Nalin Sharma, Md Mohiuddin et al.
<jats:p><p>HLA loss of heterogeneity (HLA LOH) and tumor neoantigen burden in relationship to clinical outcome variables in dMMR CRC.</p></jats:p>
Keywords
phlalossheterogeneitytumorneoantigen
Related Articles
‘Narcissist’ bosses are more likely to oppose work from home, studies show. But are they right?